Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Remains as Far from FDA Approval as Ever Despite Recommendation from DSMB
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Remains as Far from FDA Approval as Ever Despite Recommendation from DSMB
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Remains as Far from FDA Approval as Ever Despite Recommendation from DSMB
Submitted by
admin
on October 15, 2011 - 1:11pm
Source:
OTC Equity
News Tags:
Cyclacel
Sapacitabine
acute myeloid leukemia
leukemia
Headline:
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Remains as Far from FDA Approval as Ever Despite Recommendation from DSMB
Do Not Allow Advertisers to Use My Personal information
